Cargando…
Immune modulation for cancer therapy
BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathw...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/ https://www.ncbi.nlm.nih.gov/pubmed/25211661 http://dx.doi.org/10.1038/bjc.2014.348 |
_version_ | 1782348741267685376 |
---|---|
author | Naidoo, J Page, D B Wolchok, J D |
author_facet | Naidoo, J Page, D B Wolchok, J D |
author_sort | Naidoo, J |
collection | PubMed |
description | BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). METHODS: Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. RESULTS: As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. CONCLUSIONS: This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents. |
format | Online Article Text |
id | pubmed-4264429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42644292014-12-16 Immune modulation for cancer therapy Naidoo, J Page, D B Wolchok, J D Br J Cancer Minireview BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). METHODS: Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. RESULTS: As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. CONCLUSIONS: This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents. Nature Publishing Group 2014-12-09 2014-09-11 /pmc/articles/PMC4264429/ /pubmed/25211661 http://dx.doi.org/10.1038/bjc.2014.348 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Minireview Naidoo, J Page, D B Wolchok, J D Immune modulation for cancer therapy |
title | Immune modulation for cancer therapy |
title_full | Immune modulation for cancer therapy |
title_fullStr | Immune modulation for cancer therapy |
title_full_unstemmed | Immune modulation for cancer therapy |
title_short | Immune modulation for cancer therapy |
title_sort | immune modulation for cancer therapy |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/ https://www.ncbi.nlm.nih.gov/pubmed/25211661 http://dx.doi.org/10.1038/bjc.2014.348 |
work_keys_str_mv | AT naidooj immunemodulationforcancertherapy AT pagedb immunemodulationforcancertherapy AT wolchokjd immunemodulationforcancertherapy |